Forgoing chemotherapy for stage 1 breast cancer: 4 million euros for large-scale international study

KWF Dutch Cancer Society dedicates 4.1 million euros for large-scale international research into forgoing chemotherapy in women with early-stage triple-negative breast cancer. The Netherlands Cancer Institute leads the OPTImaL trial looking into safely forgoing chemotherapy in women with many immune cells around their tumors, as this indicates an excellent prognosis. The study will take place in Belgium, Germany, Ireland, Sweden, Italy, and the Netherlands over the next eight years. The results may mean that thousands of women will no longer undergo chemotherapy worldwide.